<DOC>
	<DOC>NCT00435760</DOC>
	<brief_summary>This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide compared to placebo and tiotropium in patients with severe COPD after a single dose treatment.</brief_summary>
	<brief_title>Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description>This is a single dose, randomised, double-blind, double-dummy, 3 period cross-over, placebo controlled, multinational, multicentre trial.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Males and females aged ≥ 40 years Current or exsmokers of ≥ 10 packyear Clinical diagnosis of severe stable COPD History or current diagnosis of asthma, allergic rhinitis, or atopy Respiratory tract infection or acute COPD exacerbation in the last 6 weeks Hospitalised for an acute COPD exacerbation in the last 3 months Evidence of contraindicated use of anticholinergic drugs</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>